Freestone Grove Partners LP Syndax Pharmaceuticals Inc Transaction History
Freestone Grove Partners LP
- $13.2 Trillion
- Q2 2025
A detailed history of Freestone Grove Partners LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 15,457 shares of SNDX stock, worth $232,627. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,457
Previous 16,964
8.88%
Holding current value
$232,627
Previous $208 Million
30.54%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
247Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$128 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$119 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$87.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$75.8 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$61.2 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $851M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...